C-Reactive protein reduction rate following initiation of anti-tumor necrosis factor α induction therapy predicts secondary loss of response in patients with Crohn's disease

References

• Ford AC, Sandborn WJ, Khan KJ, et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:644–659.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Yan S, Bala M, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology. 2005;128:862–869.
   PubMed Web of Science ®Google Scholar
• Rogler G. Top-down or step-up treatment in Crohn's disease? Dig Dis. 2013;31:83–90.
   PubMed Web of Science ®Google Scholar
• Lin MV, Blonski W, Lichtenstein GR. What is the optimal therapy for Crohn's disease: step-up or top-down? Expert Rev Gastroenterol Hepatol. 2010;4:167–180.
   PubMed Web of Science ®Google Scholar
• Rubin DT, Sederman R. Maintenance of response to biologic therapy in Crohn's disease is improved with “Early Use” V. “Step Up” treatment using health claims data. Gastroenterology. 2009;136:A-146.
   Web of Science ®Google Scholar
• Roda G, Jharap B, Neeraj N, et al. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol. 2016;7:e135.
   PubMed Web of Science ®Google Scholar
• Lees CW, Ali AI, Thompson AI, et al. The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up. Aliment Pharmacol Ther. 2009;29:286–297.
   PubMed Web of Science ®Google Scholar
• Qiu Y, Chen BL, Mao R, et al. Systematic review with meta-analysis: loss of response and requirement of anti-TNFα dose intensification in Crohn's disease. J Gastroenterol. 2017;52:535–554.
   PubMed Web of Science ®Google Scholar
• Park KT, Colletti RB, Rubin DT, et al. Health insurance paid costs and drivers of costs for patients with Crohn's Disease in the United States. Am J Gastroenterol. 2016;111:15–23.
   PubMed Web of Science ®Google Scholar
• Van Assche G, Lewis JD, Lichtenstein GR, et al. The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety. Am J Gastroenterol. 2011;106:1594–1602. Quiz 1593, 1603.
   PubMed Web of Science ®Google Scholar
• Hong SN, Kim HJ, Kim KH, et al. Risk of incident Mycobacterium tuberculosis infection in patients with inflammatory bowel disease: a nationwide population-based study in South Korea. Aliment Pharmacol Ther. 2017;45:253–263.
   PubMed Web of Science ®Google Scholar
• Kopylov U, Seidman E. Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease. Therap Adv Gastroenterol. 2016;9:513–526.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, McGovern D. Using markers in IBD to predict disease and treatment outcomes: rationale and a review of current status. Am J Gastroenterol Suppl. 2016;3:17–26.
   Google Scholar
• Kopylov U, Ben-Horin S, Seidman E. Therapeutic drug monitoring in inflammatory bowel disease. Ann Gastroenterol. 2014;27:304–312.
   PubMedGoogle Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–1549.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362:1383–1395.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132:52–65.
   PubMed Web of Science ®Google Scholar
• Ben-Horin S, Kopylov U, Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmunity Rev. 2014;13:24–30.
   PubMed Web of Science ®Google Scholar
• Thomson ABR, Gupta M, Freeman HJ. Use of the tumor necrosis factor-blockers for Crohn's disease. World J Gastroenterol. 2012;18:4823–4854.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol. 2009;104:760–767.
   PubMed Web of Science ®Google Scholar
• Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749–753.
   PubMed Web of Science ®Google Scholar
• Peters CP, Eshuis EJ, Toxopeus FM, et al. Adalimumab for Crohn's disease: long-term sustained benefit in a population-based cohort of 438 patients. J Crohns Colitis. 2014;8:866–875.
   PubMed Web of Science ®Google Scholar
• Reinisch W, Wang Y, Oddens BJ, et al. C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I. Aliment Pharmacol Ther. 2012;35:568–576.
   PubMed Web of Science ®Google Scholar
• Magro F, Rodrigues-Pinto E, Santos-Antunes J, et al. High C-reactive protein in Crohn's disease patients predicts nonresponse to infliximab treatment. J Crohns Colitis. 2014;8:129–136.
   PubMed Web of Science ®Google Scholar
• Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut. 2009;58:492–500.
   PubMed Web of Science ®Google Scholar
• Park SH, Hwang SW, Kwak MS, et al. Long-term outcomes of infliximab treatment in 582 Korean patients with Crohn's Disease: a hospital-based cohort study. Dig Dis Sci. 2016;61:2060–2067.
   PubMed Web of Science ®Google Scholar
• Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology. 2009;137:1628–1640.
   PubMed Web of Science ®Google Scholar